MiMedx To Present At Canaccord Genuity Virtual MedTech & Diagnostics Forum

MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MiMedx or the Company), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief Financial Officer, will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020, beginning at 9:30 am, Eastern Time.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Thursday, November 12, 2020

Information

Tags:

Canaccord Genuity, Finance, Genuity, Medtech, Zimmer Biomet Robotics, MiMedx, NASDAQ, Service companies, Companies

Geotags:

Marietta, Us

Organisation:

MIMEDX GROUP, INC

Summary

Key Points:

MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MiMedx or the Company), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief Financial Officer, will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020, beginning at 9:30 am, Eastern Time.
A live webcast of the presentation will be available on the Events page of the Investors section of the Companys website or through the conference site by using the link below.
A replay of the webcast will be available for approximately 45 days on the Companys website at www.mimedx.com following the conclusion of the presentation.
MiMedx has supplied more than two million allografts, through both direct and consignment shipments.

MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief Financial Officer, will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020, beginning at 9:30 am, Eastern Time.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website or through the conference site by using the link below.

Date: Thursday, November 19, 2020
Time: 9:30 AM ET
Webcast: https://wsw.com/webcast/canaccord44/mdxg/2454624

A replay of the webcast will be available for approximately 45 days on the Company’s website at www.mimedx.com following the conclusion of the presentation.

About MiMedx
MiMedx^® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION^® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contact
Hilary Dixon
Investor Relations & Corporate Communications
770.651.9066
[email protected]